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Background: Despite the genotype 4 has become the dominant cause of hepatitis E disease in China, none
antigen derived from genotype 4 of hepatitis E virus (HEV) was used in current commercial anti-HEV immunoassay,
and the serological reactivity of antigen derive from genotype 4 is not well-charactered.
Methods: We expressed and purified the 4 main immuno-dominant epitopes derived from genotype 1 and 4
including ORF2 (410-621aa) of genotype 4, ORF3 (47-114aa) of genotype 4, ORF2 (396-606aa) of genotype 1 and
ORF3 (56-123aa) of genotype 4.
Results: The ORF2 of genotype 4 displayed good diagnostics performance according to ROC analysis using
in-house panel, and the immunoassays based the ORF2 of genotype 4 was then developed to detect the anti-HEV
IgG antibodies and evaluated further in 530 anti-HEV IgG positive specimens and 380 negative specimens. The
sensitivity and the specificity is 98.1% (520/530) and 94.7% (360/380) for immunoassay based on ORF2 of genotype
4, 96.6% (512/530) and 92.6% (352/380) for commercial immunoassay based on genotype 1. It is noted that all of
the positive samples will be detected by combing two assays together. The anti-HEV immunoassays based on
genotype 4 are in accordance with Chinese anti-HEV national standard,and show an good agreement of 95.8% with
commercial assay (kappa=0.913, P=0.014).
Conclusions: The immunoassay based on ORF2G4 displays good performance, and combining assay based on
genotype 1 together with genotype 4 will benefit the HEV diagnosis in large scale samples.
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Hepatitis E caused by Hepatitis E Virus (HEV) has been
reported all over the world. Usually hepatitis E is endemic
in developing countries associated with contaminated
drinking water. In China, there are about 120,000 people
infected with HEV and lead to 707 deaths in Xinjiang,
during 1986–1988 [1]. In developed countries, hepatitis E
occurs sporadically either related to travel to endemic
areas or caused by autochthonous strains [2]. Now many
animal including wild boars, deer, pig, horses, rabbits etc.,* Correspondence: zhangheqiu2004@yahoo.com.cn
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reproduction in any medium, provided the orwas found to carry the virus, which is the potential reason
contributed to the transmission of HEV [3,4].
The completion of the HEV genome facilitated the
development of the HEV diagnostics. The HEV genome
is a single-stranded, positive-sense RNA encoding three
open reading frames (ORFs) named ORF1, ORF2 and
ORF3 [5]. Now recombinant ORF2 and ORF3 antigens or
immunodominant peptides were widely used in commer-
cial HEV serological test including detecting IgM, IgG,
IgA antibodies against HEV [6,7]. Recently, RT-PCR is a
new way to detect HEV-RNA [8]. However, in addition to
high expense and laborious work of the RT-PCR, HEV
RNA exists only shortly in the blood and feces among
sub-clinical cases [9]. Therefore, HEV immunoassays re-
main important and irreplaceable in the diagnosis of HEVal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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infection is often endemic.
Now four distinct genotypes (genotypes1-4) have been
identified according to the phylogenic analyze of the
HEV [10]. In spite only one serotype was found, recent
report revealed that there are different antigenicity of
HEV ORF2 between genotype 1 and 3 [11]. It is reported
that anti-HEV were not detectable in a patient infected
with HEV strain US-1 using an assay based on Burmese
and Mexican strains [12]. Anti-ORF3 antibodies were
detected in monkey infected with genotype 1 and 2 but
not in monkey infected with genotype 3 or 4 [13]. All
above evidences mean the sensitivity of the HEV sero-
logical test in definite geographic area is depend on the
prevailed genotype and the immunodominant antigen
used in the immunoassays.
Genotype 4 is originally identified in China in 2002, and
with one nucleotide insertion in ORF2 which leaded to
increased 13 amino acids at its C terminal comparing with
other genotype [14]. Our collaborated research revealed
that the ORF3 polypeptide of genotype 4 displayed stron-
ger reactivity than that of genotype 1 in the sera from
monkeys infected with genotype 4 [15]. Immunoassays
based on ORF2 immuno-dominant epitope derived from
HEV genotype 4 detected some cases of acute hepatitis E
undetected by a commercial assay [16]. That means the
antigen derived from genotype 4 is important in diagnosis
anti-HEV especially in China where the genotype 4 and 1
were prevalent in recent report [17,18]. But until now, no
commercial assay is developed based on antigen derived
from genotype 4, and little is known about the sensitivity
and specificity of immunoassay based on antigen derived
from genotype 4 in large random samples of patients
infected with HEV.
The aim of this study is to develop the immunoassay
based on recombinant immuno-dominant HEV antigen
derived from genotype 4 which has never been used
in commercial test. Total of 910 samples were used to
evaluate the sensitivity and specificity of the new HEV
immunoassay comparing with commercial immunoassay
based on genotype 1.
Results
1. Selection and expression of HEV immuno-dominant
epitopes derive from genotype 4 and 1.
The selection of the immuno-dominant antigen is the
key for the development of the immunoassay. The ORF2G1
(396-606aa, genotype 1) is well-characterized as an immu-
noreactive antigen and widely used in commercial anti-
HEV immunoassay. Because the full length ORF2 from
genotype 4 is 14 amino acids longer than that from geno-
type 1 for a single nucleotide insertion, the correspondingORF2 immuno-domain of genotype 4 (ORF2G4) is 410-
621aa. The sequences alignment revealed that there were
20 amino acids (9.52%) different between genotype 4 and
1 (Figure 1A), which lead to a little change in hydrophobi-
city analyzed by the BioSun software (Figure 2).
The nucleotide insertion of genotype 4 also changes the
sequences of ORF3. The ORF3 of genotype 4 is 9 amino
acids shorter than that from genotype 1 at the N terminal.
However, polypeptide at the N terminal of ORF3 display
no immunoreactive with anti- HEV positive sera includ-
ing both genotype 4 (1-60aa) and genotype 1(1-51aa) in
our collaborated researches [19]. The ORF3 (56-123aa) of
genotype 1 (ORF3G1) and ORF3 (47-114aa) of genotype
4 (ORF3G4) were selected instead of the whole ORF3.
The sequences alignment (Figure 1B) revealed that 20aa
(29.4%) is different between he genotype 4 and 1 ORF3
selected, which lead to much change in hydrophobicity
(Figure 3).
Above 4 antigens were expressed in insoluble form.
Following purification, each product showed one clear
band of the expected molecular mass on SDS–PAGE.
2. Reactivity of ORF2G1, ORF2G4, ORF3G1 and
ORF3G4 detected by in-house panel.
The in-house panel was used to determine the reactiv-
ity of HEV by indirect ELISA including 20 anti-HEV
IgG positive sera and 20 anti-HEV IgG negative sera.
Both ORF2 antigens derived from genotype 1 and 4 dis-
play strong reactions with all of 20 anti-HEV positive
sera. Comparably, the antigenicity of ORF3 is weaker
than that of ORF2. Only 12 of 20 positive sera were
reacted with ORF3. There are no sera positive with
ORF3 and negative with ORF2. That means that adding
ORF3 antigen could have little help to acquire high sen-
sitivity of anti-HEV detection in the in-house panel.
However, there are 2 HEV positive sera display incon-
sistent results between the ORF3 antigen of genotype 1
and 4 (Table 1). Further ROC curve showed that the
ORF2G4 achieved best performance with area under the
curve 0.988 (Figure 4), and was selected to develop the
HEV immunoassay.
3. Establish and evaluate HEV–IgG Immunoassay
based on the ORF2G4 antigen.
400 plasma of health blood donor were used to deter-
mine the cut-off value of the assay. The cut-off value
was 0.18 based on the average value plus triple standard
deviation according to the statistical analysis. The speci-
men with S/CO ratio≥1.0 is positive, the specimen with
S/CO ratio< 1.0 is negative.
The Chinese National Reference was used to evaluate
the performance of our immunoassay based on
Figure 1 The alignment of the deduced sequences of the amino acids of HEV sequences. A is the alignment results of ORF2 between
genotype 1 and 4; B is the alignment results of ORF3 between genotype 1 and 4; identical amino acids indicated by dashes.
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imens, 4 sera with serial dilution, 1 precision specimens
in Chinese National Reference for anti-HEV antibody
detection. Our result is as follows: all of the positive and
negative specimens were correctly identified. The sensi-
tivity test using the sera with serial dilution is 1:16 and
precision CV is 4%. These results are consistent with
the national standard.
We use a total of 910 specimens to evaluate our anti-
HEV immunoassay. 530 HEV IgG positive samples and
380 negative samples (190 HBV infected sample, 190
health blood donor) were included. The results were
shown in Table 2. The sensitivity of IgG assay basedFigure 2 The merge of hydrophobicity of ORF2 from genotype 1 and
hydrophobicity of ORF2 of genotype 1, and the red line is of genotype 4.on genotype 4 is 98.1% (520/530) in the anti-IgG posi-
tive sample, which is little higher than that of commer-
cial immunoassay based on genotype 1 (96.6%, 512/530)
(χ2=2.384, P=0.125). The specificity of assay based on
genotype 4 and 1 is 94.7% (360/380) and 92.6% (352/
380) respectively in anti-IgG negative panel. There are
no significant difference between two assays(χ2=1.767,
P=0.184).
To better understand the influence brought by differ-
ent HEV genotype antigen, we analyzed the agreement
between the 2 immunoassay in positive and negative
samples respectively. The results were summarized in
Table 3. The two tests gave an excellent agreement of4 analyzed by the BioSun software. The green line is the
Figure 3 The merge of hydrophobicity of ORF3 from genotype 1 and 4 analyzed by the BioSun software. The green line is the
hydrophobicity of ORF3 from genotype 1, and the red line is from genotype 4.
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samples. It is noted there is no samples negative with
both test in positive panel and the detectable rates could
reach 100% in 530 positive samples when combining
two assays together.
Discussion
The antigen used in the immunoassay is the key to ac-
quire high sensitivity and specificity. It was reported that
ORF2 (394-606aa) of the genotype 1 expressed in E.coli
contained the conformational neutralizing epitopes, and
display high immuno-reactivity with both acute and con-
valescent sera of HEV patients [20]. But the full-length
ORF2 expressed will mask some epitope, and display
weak immunoreactivity in detecting anti-HEV antibodies
[21]. Now, ORF2 (394-606aa) of the genotype 1 is the
main antigen widely used in the diagnosis of anti-HEV
antibodies [22]. However, the valuable epitopes derived
from genotype 4 has not yet been well investigated.
Using the conformational antibodies 1G10 of genotype
4, ORF2 (477-613aa) was confirmed as conformational-
dependent epitope, and its flanking amino acid residues
is important to form the stable conformation of the
epitope [23]. Our previous research found the ORF2
(384-673aa) of genotype 4 predicted by bio-informationTable 1 Comparison between the ORF3G1 and ORF3G4




Negative 1 22comprise epitope mentioned above and displayed good
reactivity with serum of infected patients and monkey
inoculated with HEV experimentally. In this paper, we
confirmed the results again that the ORF2 (410-621aa)
of genotype 4 is immunoreactive just as ORF2 (374-
606aa) of genotype 1.Figure 4 The ROC curve of the ORF2G1, ORF2G4, ORF3G1,
ORF4G4 analyzed by SPSS software derived from an
in-house panel.
Table 2 The results of anti-HEV IgG Immunoassay based
on genotype 1 and 4
Group Number positive by assay
based on genotype 1
positive by assay
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antigen used in anti-HEV detection. Some authors reveal
that the assay based on ORF3 could detect some early
antibodies negative with ORF2 [24,25]. While others
found the kits using both ORF3 and ORF2 did not dis-
play more sensitive than the one used ORF2 alone [26].
As samples used were from convalescent and not early
infected patients, we found there were no samples with
anti-ORF3 positive but anti-ORF2 negative results in this
study. However, our data revealed that the ORF3 of
genotype 1 and 4 displayed different reactive patterns in
the in-house panel, and it is reported that the ORF3 dis-
play genotypic difference in others’ researches [19]. That
suggested the ORF3 antigen could be of potential use in
HEV serotype detection.
Anti-IgG was mainly appear in the convalescent se-
rum,while anti-HEV IgG also can be detected in some
acute case patient [27]. That means the HEV IgG detec-
tion was used not only in epidemiology of HEV but also
in diagnosis of acute HEV infection. Although there is
no statistical significance, the anti-HEV assays based on
genotype 4 detected little more positive samples than
commercial assay did. Interestingly, some samples failed
to detect in commercial assay based on genotype 1 could
be detectable by the assay based on genotype 4, and the
sensitivity would be improved to 100% if we combined
two assays together. There are two reason contributed
for the adding effect. One is the different antigenicity
of HEV ORF2 between different genotype. According
to the epidemiological study,the genotype 1 and 4 are
prevalent in China. That means using of antigen derived
from genotype 1 and 4 will benefit the HEV detection in
China. It is reported that anti-HEV were not detectableTable 3 Agreement between immunoassay based on HEV
genotype 1 and 4
Immunoassay based
on genotype 4




The normal number is the value derive from 530 HEV positive samples, and
the italic and underline number is the value derive from 380 HEV
negative samples.in a patient infected with HEV genotype 3 using an assay
based on other genotype [12]. Therefore, it is necessary
to develop the HEV immunoassay based on four dif-
ferent genotype discovered. The other reason is the vari-
ous technology and procedure used by two test lead to
adding affect of the diagnosis. It is well-known that the
WHO recommends using 2 ELISA tests to reduce the
HCV transmission by blood compounds [28]. Now, it is
urged by some researchers that HEV will be transmitted
by blood especially in epidemic area [29]. Our study pro-
vided the new HEV immunoassay which could comple-
ment for current commercial test.
Conclusion
In this research, we evaluated the main immuodominant
epitope of HEV ORF2 and ORF3 derived respectively
from genotype 4 and genotype 1. The immunoassay
based on ORF2 of genotype4 (410-621aa) was developed
and displayed good performance comparing with com-
mercial kits based on genotype1 in 910 clinical samples
and blood donor. Our results reveal that combing assay
based on genotype 1 together with the one based on




A total of 910 specimens were used to evaluate the anti-
HEV immunoassay: 530 anti-HEV IgG positive speci-
mens were from convalescent patients, 190 negative spec-
imens were collected from healthy blood donors and 190
from HBV patients. The specimens were provided by In-
stitute of Hepatitis, Youan Hospital, Beijing, China; Anhui
Province Municipal Hospital, Hefei, China; and Shanghai
public health center, Shanghai, China. 400 specimens of
healthy blood donor were used for calculating the cut-off
value provided by the Blood Center of Beijing Red Cross.
20 samples with anti-HEV IgG antibody positive and 20
negative samples were used as lab panel to screening the
epitopes were provided by Youan Hospital. These blood
and plasma specimens were stored at −70°C. This study
was approved by the Ethics Committees of the related
hospitals and research institutes.
HEV antigen preparation
Total of 4 antigens were selected in this study includ-
ing ORF2 derived from genotype 1 [GenBank: M73218]
(396-606aa, ORF2G1), ORF2 derived from genotype 4
[GenBank: AJ272108] (410-620aa, ORF2G4), ORF3 derived
from genotype 1 [GenBank: M73218] (1-123aa, ORF3G1),
ORF3 derived from genotype 4 [GenBank: AJ272108]
(47-114aa, ORF3G4). The above 4 gene fragments were
PCR from HEV genotype 4 or genotype 1 T-easy vector,
and inserted into the pBVIL-1 vector. All of the 4 antigens
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17.5 kDa of interleukin (IL)-1βand were purified success-
fully using ionexchange chromatography and were then
freeze-dried.
Indirect ELISA to detect the HEV- IgG
Microplates coating with 0.25 μg recombinant HEV anti-
gen were incubated in 100 mmol/L phosphate buffer
(pH7.4) overnight at 4°C, and blocked with 2% BSA in the
phosphate buffer at 4°C for 3h. 100 μL of the sample were
added at 1:10 dilution in the buffer (100 mmol/L sodium
phosphate buffer pH7.5 containing 10% goat serum and
0.05% Tween) at 37°C for 1h. the 100 mmol/L sodium
phosphate buffer (pH7.5) containing 0.05% Tween were
used to wash the plates five times. After incubated for 30
min at 37°C with 1:25000 diluted HRP-conjugated mono-
clonal antibodies against human IgG, the plates were
washing again. After the visualized reaction with substrate
buffer (50 mmol/L sodium phosphate-citric acid buffer,
pH 5.0 containing 0.4 mg/mLTMB and 0.4 μL/mL of 30%
hydrogen peroxide), the reaction was stopped by 50 μL of
2 mol/L sulfuric acid, and the OD450 was measured in a
microplate ELISA reader. The cut-off value was calculated
according to method 2.4.
The evaluation of the immunoassay with the China
National anti-HEV Panel
The China national anti-HEV panel was used to assess
anti-IgG HEV immunoassays based on ORF2G4. The
panel included 30 true negative, 10 positive specimens, 1
specimens with dilution at 1:4, 1:8, 1:16, 1:32, and 1 preci-
sion specimens repetitively tested by 10 time. The stan-
dards of the China National anti-HEV IgG Panel were as
follows: negative ratio is equal or more than 29/30, and
the positive ratio is 10/10; the sensitivity test is more than
1/16 and precision CV is lower than 15% (n = 10).
Comparison of the immunoassay with other commercial
HEV ELISA kits
The anti-HEV IgG antibody detection kit (indirect assay,
Wan Tai Pharmaceutical Co., Lot number: EG 20090704,
Xiamen, China) based on ORF2 of genotype 1 was used
to evaluated the HEV antibodies assay based on HEV
ORF2 of genotype 4. The above assays were performed
according to the manufacturer’s instructions.
Statistics
All data were analyzed by statistical software SPSS
16.0. Receiver operator characteristic curve (ROC) was
conducted to evaluate the diagnostic significance of
recAg-1-12. Kappa test was conducted to evaluate the
consistency of qualitative results. P<0.05 was consid-
ered statistically significant.Abbreviations
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genotype 1; ORF3G1: The ORF3 of genotype 1.
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